Experimental drug Contrave(R) (naltrexone SR/bupropion SR) for the treatment of obesity has been recommended for approval by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee. The Committee (Panel) voted 13 to 7 in favor of approving Contrave for long-term use among certain obese...